Brokerages Expect Assembly Biosciences Inc (NASDAQ:ASMB) Will Post Quarterly Sales of $3.90 Million

Wall Street analysts expect Assembly Biosciences Inc (NASDAQ:ASMB) to announce sales of $3.90 million for the current quarter, according to Zacks. Four analysts have made estimates for Assembly Biosciences’ earnings. The highest sales estimate is $4.00 million and the lowest is $3.70 million. Assembly Biosciences reported sales of $3.22 million in the same quarter last year, which would suggest a positive year-over-year growth rate of 21.1%. The business is expected to announce its next quarterly earnings report on Wednesday, August 14th.

On average, analysts expect that Assembly Biosciences will report full-year sales of $15.11 million for the current fiscal year, with estimates ranging from $14.00 million to $15.89 million. For the next fiscal year, analysts forecast that the company will report sales of $15.51 million, with estimates ranging from $14.00 million to $16.50 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side analysts that that provide coverage for Assembly Biosciences.

Assembly Biosciences (NASDAQ:ASMB) last announced its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported ($1.05) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($1.06) by $0.01. Assembly Biosciences had a negative net margin of 671.48% and a negative return on equity of 56.45%. The firm had revenue of $3.89 million for the quarter, compared to analyst estimates of $3.81 million.

ASMB has been the subject of several research analyst reports. William Blair reissued a “buy” rating on shares of Assembly Biosciences in a research note on Tuesday, July 16th. Chardan Capital restated a “hold” rating on shares of Assembly Biosciences in a report on Sunday, June 30th. Zacks Investment Research cut ExlService from a “hold” rating to a “sell” rating in a report on Wednesday, July 10th. Finally, BidaskClub cut Walgreens Boots Alliance from a “sell” rating to a “strong sell” rating in a report on Monday, June 24th. One analyst has rated the stock with a sell rating, three have issued a hold rating and four have issued a buy rating to the stock. Assembly Biosciences presently has a consensus rating of “Hold” and an average price target of $41.20.

Institutional investors have recently bought and sold shares of the business. Deutsche Bank AG boosted its holdings in shares of Assembly Biosciences by 29.8% during the 4th quarter. Deutsche Bank AG now owns 54,606 shares of the biopharmaceutical company’s stock worth $1,234,000 after buying an additional 12,525 shares in the last quarter. New York State Common Retirement Fund lifted its holdings in shares of Assembly Biosciences by 15.3% in the 4th quarter. New York State Common Retirement Fund now owns 23,300 shares of the biopharmaceutical company’s stock worth $527,000 after purchasing an additional 3,100 shares in the last quarter. Tibra Equities Europe Ltd bought a new position in shares of Assembly Biosciences in the 1st quarter worth $918,000. Emerald Mutual Fund Advisers Trust lifted its holdings in shares of Assembly Biosciences by 13.3% in the 1st quarter. Emerald Mutual Fund Advisers Trust now owns 418,143 shares of the biopharmaceutical company’s stock worth $8,233,000 after purchasing an additional 49,230 shares in the last quarter. Finally, FMR LLC lifted its holdings in shares of Assembly Biosciences by 136.0% in the 4th quarter. FMR LLC now owns 443,036 shares of the biopharmaceutical company’s stock worth $10,021,000 after purchasing an additional 255,336 shares in the last quarter. Hedge funds and other institutional investors own 86.44% of the company’s stock.

ASMB stock traded down $0.97 during midday trading on Friday, reaching $13.00. 213,042 shares of the company were exchanged, compared to its average volume of 357,036. The company has a debt-to-equity ratio of 0.06, a current ratio of 7.97 and a quick ratio of 7.97. The stock’s 50-day simple moving average is $14.11. Assembly Biosciences has a one year low of $12.75 and a one year high of $44.65. The firm has a market capitalization of $332.15 million, a price-to-earnings ratio of -3.27 and a beta of 1.46.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc operates as a clinical-stage biotechnology company in the United States. The company develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome.

Further Reading: How much money do you need to begin day trading?

Get a free copy of the Zacks research report on Assembly Biosciences (ASMB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Assembly Biosciences (NASDAQ:ASMB)

Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.